Opposing roles of eosinophils in cancer
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Eosinophils are a subset of granulocytes mostly known for their ability to combat parasites and induce allergy. Although they were described to be related to cancer more than 100 years ago, their role in tumors is still undefined. Recent observations revealed that they display regulatory functions towards other immune cell subsets in the tumor microenvironment or direct cytotoxic functions against tumor cells, leading to either antitumor or protumor effects. This paradoxical role of eosinophils was suggested to be dependent on the different factors in the TME. In addition, the clinical relevance of these cells has been recently addressed. In most cases, the accumulation of eosinophils both in the tumor tissue, called tumor-associated tissue eosinophilia, and in the peripheral blood were reported to be prognostic markers for a better outcome of cancer patients. In immunotherapy of cancer, particularly in therapy with immune checkpoint inhibitors, eosinophils were even shown to be a potential predictive marker for a beneficial clinical response. A better understanding of their role in cancer progression will help to establish them as prognostic and predictive markers and to design strategies for targeting eosinophils.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Considering that eosinophils can have a role in the response against cancer,17–20 an elevated AEC might be a marker of effectiveness in some patients.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eosinophils Sustain Adipose Alternatively Activated Macrophages Associated with Glucose Homeostasis
Wu, D., Molofsky, A. B., Liang, H.-E., Ricardo-Gonzalez, R. R., Jouihan, H. A., Bando, J. K., Chawla, A., & Locksley, R. M. (2011) · Science · doi:10.1126/science.1201475 · Cited by 1,376
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Rothenberg, M. E., & Hogan, S. P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090720 · Cited by 1,356
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Type 2 innate lymphoid cells control eosinophil homeostasis
Nussbaum, J. C., Van Dyken, S. J., von Moltke, J., Cheng, L. E., Mohapatra, A., Molofsky, A. B., Thornton, E. E., Krummel, M. F., Chawla, A., Liang, H.-E., et al. (2013) · Nature · doi:10.1038/nature12526 · Cited by 1,068
Eosinophils: changing perspectives in health and disease
Rosenberg, H. F., Dyer, K. D., & Foster, P. S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3341 · Cited by 989
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense
Yousefi, S., Gold, J. A., Andina, N., Lee, J. J., Kelly, A. M., Kozlowski, E., Schmid, I., Straumann, A., Reichenbach, J., Gleich, G. J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1855 · Cited by 967
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
Inflammation and necrosis promote tumour growth
Vakkila, J., & Lotze, M. T. (2004) · Nature Reviews Immunology · doi:10.1038/nri1415 · Cited by 690
Clutterbuck, E., Hirst, E., & Sanderson, C. (1989) · Blood · doi:10.1182/blood.v73.6.1504.1504 · Cited by 687
Research works printed but not linked: 1
- Feldbausch F (1900) The occurrence of eosinophilic leukocytes in tumours. Archiv Fur Pathologische Anatomie Physiologie Fur Klinische Medicin 161(1):1–18
Cited by
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
“Eosinophils are commonly seen in the TME (96, 97).”
BackgroundSalemme, V., Centonze, G., Cavallo, F., Defilippi, P., & Conti, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.610303 · Cited by 247
Contributions of Eosinophils to Human Health and Disease
Klion, A. D., Ackerman, S. J., & Bochner, B. S. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032756 · Cited by 244
“Some of the more intriguing recent information on this topic comes from analyses of tumor biopsies and correlations between prognosis and numbers of eosinophils in the tumor microenvironment, detected histologically or based on the presence of eosinophil-specific gene signatures (74, 75).”
BackgroundŞahin, T. K., Ayasun, R., Rizzo, A., & Güven, D. C. (2024) · Cancers · doi:10.3390/cancers16213689 · Cited by 186
“Neutrophils and eosinophils, both integral components of the immune system, play distinct yet interconnected roles in cancer progression [18,19].”
BackgroundHwang, M., Canzoniero, J. V., Rosner, S., Zhang, G., White, J. R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004688 · Cited by 150
Chu, X., Zhao, J., Zhou, J., Zhou, F., Jiang, T., Jiang, S., Sun, X., You, X., Wu, F., Ren, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.015 · Cited by 164
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Jahchan, N. S., Mujal, A. M., Pollack, J. L., Binnewies, M., Sriram, V., Reyno, L., & Krummel, M. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01611 · Cited by 120
Неганова, М. Е., Liu, J., Aleksandrova, Y. R., Klochkov, S. G., & Fan, R. (2021) · Cancers · doi:10.3390/cancers13236062 · Cited by 120
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
Simon, S. C. S., Hu, X., Panten, J., Grees, M., Renders, S., Thomas, D., Weber, R., Schulze, T. J., Utikal, J. S., & Umansky, V. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1727116 · Cited by 95
“They were shown to be enriched in the tumor tissue and in the peripheral blood of patients with various solid tumor types.(8) Interestingly, this enrichment was described to have a pleiotropic relation to the prognosis of tumor patients.”
BackgroundSelf-citationProstaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4
Santiso, A., Heinemann, Á., & Kargl, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000901 · Cited by 104
Histamine in cancer immunology and immunotherapy. Current status and new perspectives
Sarasola, M. D. L. P., Delgado, M. A. T., Nicoud, M. B., & Medina, V. A. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.778 · Cited by 86
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature
Chan, K. K., MAGRO, C. M. J., Shoushtari, A. N., Rudin, C. M., Rotemberg, V. M., Rossi, A., Lezcano, C. M., Carrino, J. A., Fernández, D., Postow, M. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0508 · Cited by 78
“Peripheral blood mononuclear cell (PBMC)-derived IL-5 has also been implicated in the development of EF [28].”
BackgroundInfluentialCTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
Zheng, X., Zhang, N., Qian, L., Wang, X., Fan, P., Kuai, J., Lin, S., Liu, C., Jiang, W., Qin, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32829 · Cited by 81
Eosinophils in wound healing and epithelial remodeling: Is coagulation a missing link?
Coden, M. E., & Berdnikovs, S. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0120-390r · Cited by 67
Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722022 · Cited by 59
“Further research is needed to determine the mechanisms involved in Eo-ir, the clinical significance of high blood eosinophilia on cancer outcome, and whether eosinophils are involved in ICIT effectiveness or just a reactive “biological” phenomenon.(17,21) Given its retrospective design, our study had several inherent…”
BackgroundEosinophils in the Tumor Microenvironment
Mattei, F., Andreone, S., Marone, G., Gambardella, A. R., Loffredo, S., Varricchi, G., & Schiavoni, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_1 · Cited by 55
Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles
Arkhypov, I., Lasser, S., Petrova, V., Weber, R., Groth, C., Utikal, J. S., Altevogt, P., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176319 · Cited by 56
Self-citationProteomics and its applications in breast cancer.
Neagu, A.-N., Whitham, D., Buonanno, E., Jenkins, A., Alexa‐Stratulat, T., Tamba, B.-I., & Darie, C. C. (2021) · PubMed · Cited by 55
IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer
Jordakieva, G., Bianchini, R., Reichhold, D., Piehslinger, J., Groschopf, A., Jensen, S. A., Mearini, E. E., Nocentini, G., Crevenna, R., Zlabinger, G. J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1880687 · Cited by 51
Bai, R., Chen, N., Chen, X., Li, L., Song, W., Li, W., Zhao, Y., Zhang, Y., Han, F., Lyu, Z., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0052 · Cited by 52
Krishnan, T., Tomita, Y., & Roberts‐Thomson, R. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0070 · Cited by 42
“At last, eosinophils may play a role in the enhancement of tumor surveillance [10,11,16].”
BackgroundPileri, A., Guglielmo, A., Grandi, V., Violetti, S. A., Fanoni, D., Fava, P., Agostinelli, C., Berti, E., Quaglino, P., & Pimpinelli, N. (2021) · Cells · doi:10.3390/cells10102780 · Cited by 47
“A suggested mechanism in which STAT3 activation in neoplastic T-cells leads to eosinophil accumulation in the TME through IL-5 production by malignant T-cells was hypothesized by Fredholm et al. The authors speculated as to whether malignant T-cells may “trap” inactivated eosinophils by a high secretion of cyclooxygen…”
BackgroundInfluentialBiomarkers for precision immunotherapy in the metastatic setting: hope or reality?
Sajjadi, E., Venetis, K., Scatena, C., & Fusco, N. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1150 · Cited by 45
Helper-like innate lymphoid cells and cancer immunotherapy
Crinier, A., Vivier, É., & Bléry, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.04.002 · Cited by 41
Alves, A., Dias, M., Campainha, S., & Barroso, A. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3525 · Cited by 49
“In fact, recent studies have shown evidence that eosinophils may have both immunostimulatory and immunoinhibitory functions in tumor growth, according to the type of cancer and different stimuli in the tumor microenvironment (TME) (8,9).”
BackgroundSchwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Vasaturo, A., Bagnall, C. J., Forsyth, R. G., Dufait, I., Tuyaerts, S., Riet, I. V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005141 · Cited by 46
Jeseňák, M., Diamant, Z., Simon, D., Tufvesson, E., Seys, S., Mukherjee, M., Lacy, P., Vijverberg, S. J. H., Slisz, T., Šedivá, A., et al. (2023) · Allergy · doi:10.1111/all.15884 · Cited by 39
From Allergy to Cancer—Clinical Usefulness of Eotaxins
Zajkowska, M., & Mroczko, B. (2021) · Cancers · doi:10.3390/cancers13010128 · Cited by 42
“Recent observations have reported that they reveal regulatory functions relative to other immune cells in the tumor microenvironment or direct cytotoxic functions against cancer cells, leading to anti- or pro- tumor activity [36].”
BackgroundMa, Y., Ma, X., Wang, J., Wu, S., Wang, J., & Cao, B. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02695-y · Cited by 38
“irAEs were defined as adverse events with a potential immunologic basis that required close monitoring and/ or potential intervention with hormonal or immunosuppressive therapies [20].”
BackgroundRoccuzzo, G., Giordano, S., Fava, P., Pileri, A., Guglielmo, A., Tonella, L., Sanlorenzo, M., Ribero, S., Fierro, M. T., & Quaglino, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.733770 · Cited by 38
“However, it’s still unclear whether eosinophils may exert an anti-tumour or tumorigenic role (60).”
BackgroundHarnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 40
Giommoni, E., Giorgione, R., Paderi, A., Pellegrini, E., Gambale, E., Marini, A., Antonuzzo, A., Marconcini, R., Roviello, G., Matucci‐Cerinic, M., et al. (2021) · Immuno · doi:10.3390/immuno1030017 · Cited by 33
“Recently, the use of baseline blood cell counts used as biomarkers has been growing as they are easy, affordable, accessible, and usually routinely requested in clinical practice [46,47].”
BackgroundTakeuchi, E., Kondo, K., Okano, Y., Ichihara, S., Kunishige, M., Kadota, N., Machida, H., Hatakeyama, N., Naruse, K., Ogino, H., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15100 · Cited by 31
“36 Eosinophils were shown to recruit regulatory T cells via the production of C-C motif chemokine 22, which facilitated pulmonary metastasis in mice.”
BackgroundInfluentialEotaxins and Their Receptor in Colorectal Cancer—A Literature Review
Zajkowska, M., & Mroczko, B. (2020) · Cancers · doi:10.3390/cancers12061383 · Cited by 27
“Recent observations have revealed that they exhibit regulatory functions towards other immune cells in the tumor microenvironment or direct cytotoxic functions against cancer cells, leading to anti- or pro-tumor activity [56].”
BackgroundTakayasu, S., Mizushiri, S., Watanuki, Y., Yamagata, S., Usutani, M., Nakada, Y., Asari, Y., Murasawa, S., Kageyama, K., & Daimon, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-05400-x · Cited by 32
Caliman, E., Fancelli, S., Ottanelli, C., Mazzoni, F., Paglialunga, L., Lavacchi, D., Michelet, M. R. G., Giommoni, E., Napolitano, B., Scolari, F., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100603 · Cited by 34
Immunity and Breast Cancer: Focus on Eosinophils
Poncin, A., Onesti, C. E., Josse, C., Boulet, D., Thiry, J., Bours, V., & Jérusalem, G. (2021) · Biomedicines · doi:10.3390/biomedicines9091087 · Cited by 30
“Moreover, tumor cells or lymphocytes from TME may produce IL-5, GM-CSF, or IL-4 [22,27].”
BackgroundInfluentialHerrmann, T., Ginzac, A., Molnar, I., Bailly, S., Durando, X., & Mahammedi, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4208 · Cited by 26
Furubayashi, N., Minato, A., Negishi, T., Sakamoto, N., Song, Y., Hori, Y., Tomoda, T., Tamura, S., Kuroiwa, K., Seki, N., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s333823 · Cited by 24
Lou, Y., Marin-Acevedo, J. A., Vishnu, P., Manochakian, R., Dholaria, B., Soyano, A. E., Luo, Y., Zhang, Y., & Knutson, K. L. (2019) · Immunotherapy · doi:10.2217/imt-2018-0128 · Cited by 25
Ammann, N. L., Schwietzer, Y. F., Meß, C., Stadler, J.-C., Geidel, G., Kött, J., Pantel, K., Schneider, S. W., Utikal, J. S., Bauer, A. T., et al. (2022) · Cancers · doi:10.3390/cancers14225676 · Cited by 27
Self-citationDeciphering the role of eosinophils in solid organ transplantation
Onyema, O. O., Guo, Y., Hata, A., Kreisel, D., Gelman, A. E., Jacobsen, E. A., & Krupnick, A. S. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15660 · Cited by 22
Sibille, A., Henket, M. A., Corhay, J. L., Alfieri, R., Louis, R. E., & Duysinx, B. (2021) · Lung · doi:10.1007/s00408-021-00474-2 · Cited by 22
Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer
Wistuba‐Hamprecht, K., Gouttefangeas, C., Weide, B., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01152 · Cited by 17
“poor prognosis of patients with high LDH (16, 17), MDSC levels (17–19) or eosinophils (20) under ipilimumab.”
BackgroundZhang, S., Zeng, Z., Liu, Y., Huang, J., Long, J., Wang, Y., Peng, X., Hu, Z., & Ouyang, Y. (2020) · Aging · doi:10.18632/aging.103519 · Cited by 18
Comprehensive Analysis of the Immune and Prognostic Implication of COL6A6 in Lung Adenocarcinoma
Ma, Y., Qiu, M., Guo, H., Chen, H., Li, J., Li, X., & Yang, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633420 · Cited by 19
“B cells, dendritic cells, and eosinophils have also been reported to be associated with a favorable prognosis (32, 33, 35).”
Lung Cancer Risk among Patients with Asthma–Chronic Obstructive Pulmonary Disease Overlap
Charokopos, A., Braman, S. S., Brown, S.-A. W., Mhango, G., de-Torres, J. P., Zulueta, J. J., Sharma, S., Holguín, F., Sigel, K. M., Powell, C. A., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202010-1280oc · Cited by 19
Takeuchi, E., Ogino, H., Kondo, K., Okano, Y., Ichihara, S., Kunishige, M., Kadota, N., Machida, H., Hatakeyama, N., Naruse, K., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15191 · Cited by 19
Takeuchi, E., Okano, Y., Machida, H., Atagi, K., Kondou, Y., Kadota, N., Hatakeyama, N., Naruse, K., & Shinohara, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02994-5 · Cited by 19
Lessons learned from targeting eosinophils in human disease
Kuang, F. L., & Bochner, B. S. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00849-w · Cited by 15
“The role of eosinophils in tumorigenesis is complex and probably differs depending on context as well type of tissue (reviewed in [18, 112]).”
BackgroundRubin, L., Talmon, A., Ribak, Y., Lavie, D., Nechushtan, H., Caplan, N., Lotem, M., Shamriz, O., Adini, I., & Tal, Y. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009658 · Cited by 12
Furubayashi, N., Minato, A., Negishi, T., Sakamoto, N., Song, Y., Hori, Y., Tomoda, T., Harada, M., Tamura, S., Miura, A., et al. (2022) · Cancer Management and Research · doi:10.2147/cmar.s360473 · Cited by 14
“Eosinophils are a subset of granulocytic leukocytes with important roles in parasitic and allergic disease.(29) Recently, eosinophils have been highlighted as potential cellular biomarkers and even end-stage effector cells in cancer therapy.”
BackgroundOmero, F., Speranza, D., Murdaca, G., Cavaleri, M., Marafioti, M., Cianci, V., Berretta, M., Casciaro, M., Gangemi, S., & Santarpía, M. (2025) · Biomolecules · doi:10.3390/biom15040491 · Cited by 15
“Eosinophils show both stimulating and inhibitory activity on the immune system which varies according to cancer type and the surrounding microenvironment [105,106].”
Voutsadakis, I. A. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.03.03 · Cited by 15
“However, eosinophils may have anti-tumoral effects in the tumor micro-environment by promoting NK cells and T cells recruitment and direct cytotoxicity by production of granzymes and other cytotoxic proteins (80).”
BackgroundExcess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
Willems, M., Scherpereel, A., Wasielewski, E., Raskin, J., Brossel, H., Fontaine, A., Grégoire, M., Halkin, L., Jamakhani, M., Heinen, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148798 · Cited by 13
“Indeed, excess of eosinophils in the peripheral blood has been correlated with either a better or a worse prognosis depending on the cancer type (20, 32, 33).”
BackgroundBrown, M. C., Beasley, G. M., McKay, Z. P., Yang, Y., Desjardins, A., Randazzo, D. M., Landi, D. B., Ashley, D. M., Bigner, D. D., Nair, S. K., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006463 · Cited by 12
Gambale, E., Maruzzo, M., Messina, C. G. M., Aquino, I. D. G., Vascotto, I. A., Rossi, V., Bimbatti, D., Cavasin, N., Messina, M., Mennitto, A., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102099 · Cited by 12
Osawa, H., Shiozawa, T., Okauchi, S., Miyazaki, K., Kodama, T., Kagohashi, K., Nakamura, R., Satoh, H., & Hizawa, N. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16049 · Cited by 14
“However, PD-L1 may show different immunostaining levels depending on the site where it was collected.”
InfluentialXu, L., Jin, Y., & Qin, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106844 · Cited by 11
Sönmez, E. E., Hatipoğlu, T., Kurşun, D., Hu, X., Akman, B., Yuan, H., Danyeli, A. E., Alacacıoğlu, İ., Özkal, Ş., Olgun, A., et al. (2022) · Cells · doi:10.3390/cells11213394 · Cited by 13
“Consistent with the reports on many other cancer types [100,101], the abundance of eosinophils was associated with better overall survival for diagnostic MCL patients.”
ResultEotaxins and Their Receptor as Biomarkers of Colorectal Cancer
Zajkowska, M., Kulczyńska‐Przybik, A., Dulewicz, M., Safiejko, K., Juchimiuk, M., Konopko, M., Kozłowski, L., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122675 · Cited by 10
Solving the Conundrum of Eosinophils in Alloimmunity
Lynch, C. A., Guo, Y., Mei, Z., Kreisel, D., Gelman, A. E., Jacobsen, E. A., & Krupnick, A. S. (2021) · Transplantation · doi:10.1097/tp.0000000000004030 · Cited by 10
“Although the role of these cells is poorly defined, studies in animal models show a capacity for eosinophils in either promoting or inhibiting cancer progression through eosinophil immune effector activities.(50) For example, IL-33–activated eosinophils infiltrate melanoma and kill the cancer cells‚(51) and eosinophil…”
BackgroundRapposelli, I. G., Matteis, S. D., Lanuti, P., Valgiusti, M., Bartolini, G., Ulivi, P., Marisi, G., Pedica, F., Burgio, V., Frassineti, G. L., et al. (2021) · Cancers · doi:10.3390/cancers13020213 · Cited by 9
“Evidence exists that the TME can be regulated by eosinophils and neutrophils [52,53], possibly underlying their prognostic role in patients treated with IT.”
BackgroundEosinophils: A Friend or Foe in Human Health and Diseases
Syeda, M. Z., Tu, H., Zhang, C., Ying, S., & Shen, H. (2022) · Kidney Diseases · doi:10.1159/000528156 · Cited by 11
Physiology and pathology of eosinophils: Recent developments
Renz, H. E., Bachert, C., Berek, C., Hamelmann, E. H., Levi‐Schaffer, F., Raap, U., Simon, H., Ploetz, S. G., Taube, C., Valent, P., et al. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13032 · Cited by 12
Long noncoding RNA MyD88 functions as a promising diagnostic biomarker in hepatocellular carcinoma
Wang, Z., Gao, P., Sun, W., Rehman, A. U., Jiang, J., Xu, S., Xue, C., Zhu, C., & Qin, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.938102 · Cited by 9
“Recent studies mentioned that eosinophils may contribute to the regulation of the tumor microenvironment (33, 34).”
BackgroundSibille, A., Henket, M., Corhay, J. L., Louis, R. E., & Duysinx, B. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1695063 · Cited by 11
“Most studies, however, highlight their multiple anti-tumour effects: maturation of dendritic cells, polarisation of macrophages to an M1 phenotype, inhibition and normalisation of tumour vasculature, recruitment and activation of T lymphocytes and NK-cells, direct cytotoxic effects on tumour cells [9,10].”
BackgroundMoreira, A., Erdmann, M., Uslu, U., Vass, V., Schuler, G., & Schuler‐Thurner, B. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030210 · Cited by 10
“The role of eosinophils in allergic diseases led to several studies of the association between allergic conditions and cancer incidence [34,35].”
BackgroundMir, M. A., Aisha, S., Sofi, S., & Rasheid, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18696-7.00007-5 · Cited by 8
Wang, X., Zhao, L., Song, X., Wu, X., Krishnamurthy, S., Semba, T., Shao, S. H., Knafl, M., Coffer, L. W., Alexander, A., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00729-0 · Cited by 16
Rembalski, S., & Steinberg, J. A. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000430 · Cited by 8
Dating thrombus organization with eosinophil counts in deep venous thrombosis
Mansıroğlu, A. K., Sıncer, İ., Coşgun, M., & Güneş, Y. (2020) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2020.10.012 · Cited by 8
Interleukin‐5‐producing malignant pleural mesothelioma with eosinophilic pleural effusion
Takeuchi, E., Takahashi, N., Morizumi, S., Tamiya, H., Matsuoka, H., Naoto, K., & Yorita, K. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13652 · Cited by 9
Ikutani, M., & Nakae, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.939378 · Cited by 8
“Histological evidence for the involvement of eosinophils in human cancers exists (61–63), however, the findings are controversial (64, 65).”
BackgroundComprehensive nomogram models for prediction of checkpoint inhibitors pneumoniaPreprint
Jia, X., Liang, T., Du, Y., Du, Y., Zhang, Y., Mao, Z., Xu, L., Shen, Y., Liu, M., & Guo, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1668092/v1 · Cited by 11
Alhamwe, B. A., Yuskaeva, K., Wulf, F., Trinkmann, F., Kriegsmann, M., Thomas, M., Keber, C. U., von Strandmann, E. P., Herth, F. J. F., Kolahian, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179552 · Cited by 6
Kaľavská, K., Šestáková, Z., Mlcakova, A., Gronesova, P., Miskovska, V., Rejleková, K., Světlovská, D., Syčová-Milá, Z., Obertová, J., Palacka, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.858797 · Cited by 6
“By contrast, eosinophils have been shown to display regulatory functions towards other immune cell subsets following activation of DCs by cytokine release from eosinophil granules (48, 49).”
BackgroundInfluentialA rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma
Tsuji, A., Hiramatsu, K., Namikawa, S., Yamamoto, A., Midori, Y., Murata, Y., Tanaka, T., Nosaka, T., Naito, T., Takahashi, K., et al. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01680-y · Cited by 8
“suggested that eosinophilia after ICI administration could be regarded as a secondary phenomenon due to an immuno-allergic process [15].”
BackgroundApprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma—Persistent Updating
Georgescu, S. R., Mitran, C. I., Mitran, M. I., Matei, C., Constantin, C., Neagu, M. T., & Tampa, M. Ş. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091506 · Cited by 6
“The stimulatory effects of eosinophils on tumor progression could be influenced by certain TME-related factors [74].”
BackgroundInfluentialZheng, Z., DAI, C., Wu, Q., Xie, J., Gao, M., & Li, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762144 · Cited by 5
“…CI, con fi dence interval; BCa, bias-corrected and accelerated. granule proteins, such as major basic protein, eosinophil cationic protein (29), which contribute to the initiation and ampli fi cation of cardiac in fl ammation through direct cytotoxic effects and recruitment of other immune cells (30).”
Willems, M., Hamaïdia, M., Fontaine, A., Grégoire, M., Halkin, L., Mañá, L. V., Terres, R., Jamakhani, M., Deshayes, S., Brostaux, Y., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105418 · Cited by 5
“32 Based on the correlation observed in the retrospective analysis, the objectives of the present study are (i) to investigate the impact of eosinophils on response to therapy in cell culture and mouse models and (ii) to characterise the mechanisms involved and identify the factors that mediate…”
Cybulska-Stopa, B., Kamińska‐Winciorek, G., & Dyduch, G. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000693 · Cited by 5
Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?
Κatsoulis, Κ., Kipourou, M., & Loukides, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1960977 · Cited by 5
“unfavorable prognostic factor in T- cell leukaemia/ lymphoma cases [29,30].”
BackgroundMatsumiya, M., Sonoda, H., Yamashita, H., Kurashina, K., Takahashi, K., Ohzawa, H., Miyato, H., Matsumoto, S., Saito, S., Hosoya, Y., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-025-19075-x · Cited by 4
“…proteins, including major basic protein, 34 eosinophilic cationic protein, eosinophil-derived neurotoxin, 35 and granzyme B. 36 More recently, IL-33–stimulated eosinophils have been shown to secrete extracellular vesicles that induce tumor cell-cycle arrest and mesenchymal–epithelial…”
SPINK5 is a key regulator of eosinophil extracellular traps in head and neck squamous cell carcinoma
Zhao, C., Zhu, H., Tian, Y., Sun, Y., & Zhang, Z. (2024) · Discover Oncology · doi:10.1007/s12672-024-01513-z · Cited by 7
Liu, X., & Wang, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106887 · Cited by 4
Osawa, H., Shiozawa, T., Okauchi, S., Sasatani, Y., Ohara, G., Sato, S., Miyazaki, K., Kodama, T., Kagohashi, K., Satoh, H., et al. (2021) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10065 · Cited by 4
“The role of eosinophils in cancer immunity is still under investigation (17-22).”
BackgroundPredictive Value and Clinical Significance of Increased SSAT-1 Activity in Healthy Adults
Tappia, P. S., Maksymiuk, A. W., SITAR, D. S., Akhtar, P. S., Khatun, N., Parveen, R., Ahmed, R., Ahmed, R. B., Cheng, B. L. M., Huang, G., et al. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0023 · Cited by 4
“Eosinophilia has been linked to a wide variety of nonneoplastic disorders, as well as to neoplastic conditions [37] and an elevation in eosinophils may exert protumor effects [38,39].”
BackgroundAdoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective
Jin, G., Chang, Y., Harris, J. D., & Bao, X. (2023) · Cells Tissues Organs · doi:10.1159/000528838 · Cited by 4
“Like other innate immune cells such as macrophages and neutrophils, eosinophils display antitumor or protumor effects by either direct cytotoxic function or indirect regulatory function toward other immune cells [Simon et al., 2019].”
BackgroundLow Expression of CLEC2B Indicates Poor Prognosis in Melanoma
Zhang, Y., Li, Y., & Yan, H. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s395854 · Cited by 3
“Studies have shown that eosinophils have the regulatory function of other immune cell subsets in the tumor microenvironment or cytotoxic function to tumor cells, resulting in either antitumor or tumor-promoting effects.(24) Natural killer (NK) cells efficiently kill adjacent tumor cells, which increases in the context…”
BackgroundUchida, T., Nakagome, K., Hashimoto, K., Iemura, H., Shiko, Y., Mouri, A., Yamaguchi, O., Uchida, Y., Nagai, Y., Soma, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1574314 · Cited by 6
The cross talk between cancer cells and their microenvironments
Witz, I. P. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.09.066 · Cited by 3
Liu, D., Wu, J., Wang, H., Dong, H., Chen, L., & Jia, N. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s484027 · Cited by 3
Eosinophils restrict CRC metastasis by inhibiting pro-tumorigenic SPP1 + macrophage differentiationPreprint
Handler, K., Raju, D., Gurtner, A., Dalessi, T., Brügger, M. D., Crepaz, D., Esposito, C., Trajanoski, Z., Münz, C., Scharl, M. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.13.628333 · Cited by 7
Chen, X., Liu, H., Pan, D., Yao, Z., Han, Z., & Qu, P. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241277695 · Cited by 3
Eosinophil-associated diseases (EADs)
Melo, R. C. N., Dvořàk, A. M., & Weller, P. F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-813755-0.00008-3 · Cited by 2
Files, R., Okwu, V., Topa, N., Sousa, M., Silva, F. C., Rodrigues, P., Delgado, L., Prada, J., & Pires, I. C. R. (2024) · Animals · doi:10.3390/ani14030519 · Cited by 4
“Additionally, it is crucial to understand how these immune system cells influence cancer progression.”
BackgroundAssessment of Tissue Eosinophilic Infiltration in Invasive Mammary Carcinoma
Hasan, F., Fadhil, M. H., & Almukhtar, Z. K. S. (2024) · International Journal of Breast Cancer · doi:10.1155/2024/1514147 · Cited by 3
“…impact on the growth of the primary tumor and metastatic potential as well as the antitumor immunotherapy response; its e ff ect depends on tumor type [18], because of the growing emerging idea about the role of sex hormones in in fl uencing and regulating tissue eosinophilic in fi ltration [7, 19].”
BackgroundMatera, M. G., Rogliani, P., Bianco, A., & Cazzola, M. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020621 · Cited by 2
Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With Cancer
Khurana, S., Abu‐Sbeih, H., Ma, W., Qiao, W., Foo, W. C., Richards, D. M., Thomas, A. S., Khan, A., Zhang, H. C., & Wang, Y. (2021) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000838 · Cited by 2
“Duration of EoC symptoms (n= 26), median (IQR) (d) 120 (60-365) 30 (14-60) 0.”
BackgroundInfluential
Metadata
- Authors
- Simon, S. C. S., Utikal, J., & Umansky, V.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Umansky, Viktor
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2018-10-09
- Volume
- 68
- Issue
- 5
- Pages
- 823-833
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11028063
- OpenAlex
- W2896948312
- Semantic Scholar
- 51d1f88740bcf0f7ea77a0ef42febece0d7266cd
- Cited by
- 128
- References
- 110
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 17 · 2023: 14 · 2022: 23 · 2021: 30 · 2020: 21 · 2019: 9
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (RTG2099)
- Deutsches Krebsforschungszentrum (CA181)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- eosinophils, tumor microenvironment, antitumor immunity, tumor-associated tissue eosinophilia, prognostic factors, predictive biomarkers, immune checkpoint inhibitors, cancer immunotherapy, eosinophil-targeted therapy, granulocytes
- MeSH terms
- Cytotoxicity, Immunologic, Eosinophils, Humans, Hypersensitivity, Immunotherapy, Neoplasms, Parasitic Diseases, Prognosis, Biomarkers, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.